The U.S. Food and Drug Administration approved Novavax's Covid-19 vaccine with age restrictions after a six-week delay.

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. The vaccine's prospects were thrown into doubt after the FDA missed its April 1 target to approve the shot,

The vaccine will only be available to those at high risk from Covid—excluding those who may need it to protect a relative or friend.